Cancer News and Research

Latest Cancer News and Research

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

Nashboro Village Family Dental's initiative for childhood cancer

On Saturday, November 21, 2009 Nashboro Village Family Dental will present our First Annual Super Talent and All-Star Show. Hosted by Lelan Statom, WTVF, NewsChannel 5, this event will benefit Operation Stand Down and one of our patients that is battling chronic childhood cancer.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.

28 Oct 2009

MolecularMD moves core operations to expanded facility

MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support the expansion of its cancer molecular diagnostics business.

28 Oct 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

California Cryobank updates its Spanish website

California Cryobank (CCB), an international sperm banking leader, announced today the release of their upgraded Spanish website www.criobanco.com. Criobanco.com offers all the features of CCB's English website www.cryobank.com including online ordering, donor search capability, and extensive information on using donor sperm.

28 Oct 2009

Arrayit sells NanoPrint Microarrayer system to CENAT

Arrayit Corporation today announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies (CENAT) in Poznan, Poland. The Arrayit NanoPrint Microarrayer will be used by CENAT for scientific and medical collaborations throughout the prosperous democracy.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Critical illness insurance, an additional layer of financial protection

As breast cancer awareness month winds to a close and pink ribbons symbolizing the brave fight against this disease take their place on survivors' dressers, the fight continues. Putting the spotlight on this devastating disease has made people think about their own mortality and what would happen if they were diagnosed with a critical illness, says Frank N. Darras, America's top Long Term Disability Lawyer.

28 Oct 2009

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

28 Oct 2009

Development of VLN cigarettes for use in smoking cessation continues: 22nd Century

22nd Century Limited, LLC is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as ‘nicotine-free’ and ‘denicotinized,’ may be more effective for quitting than FDA-approved therapies.

28 Oct 2009

IPIT uses Affymetrix’s DMET Plus biomarker panel to expand the PGENI

Affymetrix, Inc. announced today that the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina in Chapel Hill is using the company’s DMET™ Plus biomarker panel to expand the Pharmacogenetics for Every Nation Initiative (PGENI).

28 Oct 2009

RadMD offers tips for efficient use of medical imaging during clinical trial process

Lengthier cancer trials and new regulations have forced pharmaceutical companies to look for new ways to minimize costs and increase efficiency. As a result, the use of medical imaging, which is currently being used in 3000 clinical trials, has come to the forefront.

28 Oct 2009

New biotechnology research center launched by SHRO

The Sbarro Health Research Organization (SHRO), a nonprofit research facility located at Temple University, will dedicate a new state-of-the-art biotechnology research center on Tuesday, October 27th, at 2 p.m. SHRO is one of the top three international laboratories, based on number of publications as ranked by the Cell Cycle Registry,

28 Oct 2009

NPC, PMC to explore comparative effectiveness research for effective health care treatments

As Congress continues its efforts to reform the health care system, the National Pharmaceutical Council (NPC) and the Personalized Medicine Coalition (PMC) will host a conference tomorrow to explore a key topic in the debate: using comparative effectiveness research (CER) to determine which health care treatments are most effective while improving the quality of patient care through personalized medicine.

28 Oct 2009